
Addressing a Critical Connection in Autism
There is currently no approved drug on the market that treats the core symptoms of Autism. At Curemark, we are working to change that.
Curemark’s lead drug candidate, CM-AT, has received “Fast Track” designation from the U.S. Food and Drug Administration (FDA) and FDA has granted Curemark a rolling review of its New Drug Application for CM-AT.
LEARN MORE